Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority
Highlights
– In a 1:2 propensity-matched, multicenter cohort of 54 patients with olfactory neuroblastoma (ONB), no definitive difference was demonstrated between adjuvant IMRT and proton beam radiotherapy (PBRT) for long-term local control, recurrence-free survival, or overall survival.
– Radiation treatment–related adverse events (grade ≥2) were numerically low (20% overall) and similar between IMRT (21%) and PBRT (18%).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.